Here are the 10-K annual reports from Elite Pharms Inc (ELTP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ELTP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELTP filings page.
Elite Pharmaceuticals, Inc. provides an overview of its business in generic and specialty oral drugs in its annual report for the year ended March 31, 2026. The company now operates as a single ANDA-based segment after pausing NDA development, and reported ANDA segment revenue of $148.9 million, up from $84.0 million in the prior year.
Elite highlights a broad portfolio of solid oral dose generics, including CNS stimulants, bariatric, cardiovascular, pain and other therapies, all manufactured at its cGMP and DEA-registered Northvale, New Jersey facility. Recent launches include Methotrexate Tablets, several opioid combination pain products, Lisdex Capsules for ADHD, Oxy APAP Tablets, and Methadone Tablets, many acquired via a June 2024 asset purchase from Nostrum Laboratories.
The company notes expiration of its long-running Precision Dose license in September 2025, termination of a Prasco non-exclusive license in March 2025, and first international shipments of amphetamine tablets under a Dexcel agreement in July 2025. Development of its SequestOx abuse-deterrent opioid candidate remains paused, and a related patent and Loxapine Capsules were impaired after reassessing expected cash flows. As of June 27, 2026, Elite had a public float valued at approximately $534 million and 1,077,196,442 common shares outstanding, supported by a workforce of 65 employees.